JANSSEN AND JANSSEN
JNJ-63733657
Focusing on early Alzheimer’s, this study tests the anti-tau antibody, JNJ-63733657, against a placebo, assessing its potential to slow disease progression. This study is for people who do not have an Alzheimer’s disease diagnosis or symptoms, rather they are at a risk for the condition.
Eligibility: Individuals that are healthy with risk of Alzheimer’s disease.
Status: RECRUITING